Roche Sees Challenge In Cancer Drug Combos; Does Data Support Price?
Executive Summary
Roche expects to face an upcoming challenge in defining the appropriate pricing model for the next generation of combination cancer therapies
You may also be interested in...
Oncologics Will Need Dual Genetic Tests For Optimally Targeted Treatments
The key to successful use of targeted oncologic therapies will be routine genetic testing for both the patient and the tumor, Fox Chase Cancer Center Senior VP Robert Ozols suggested at an American Society of Clinical Oncology briefing Dec. 2
Oncologics Will Need Dual Genetic Tests For Optimally Targeted Treatments
The key to successful use of targeted oncologic therapies will be routine genetic testing for both the patient and the tumor, Fox Chase Cancer Center Senior VP Robert Ozols suggested at an American Society of Clinical Oncology briefing Dec. 2
Tarceva Price Will Be In Bounds, OSI Says: Above Iressa, Below Gleevec
Genentech/OSI will price the EGFR inhibitor Tarceva between AstraZeneca's Iressa and Novartis' Gleevec, OSI CEO Colin Goddard, PhD, said